Could Twice-Daily aspirin save diabetic hearts?
NCT ID NCT02520921
First seen Nov 20, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This study tested whether taking aspirin twice a day (200 mg total) works better than the standard once-daily dose (100 mg) to prevent another heart attack, stroke, or urgent heart procedure in diabetic patients who recently had a heart attack. About 2,500 participants were followed for 18 months. The goal was to see if splitting the dose reduces ischemic events without causing more bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Cardiology - Lariboisiere Hospital
Paris, 75010, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin (enteric coated)
What this could lead to
If successful, this could show that a simple change in aspirin dosing reduces the risk of repeat heart attacks or strokes in diabetic patients.
What could go wrong
This is a completed Phase 4 trial, but the benefit may be small and bleeding risk could increase with higher total aspirin dose. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.